1. Home
  2. Knowledge Base
  3. References
  4. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer

Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B (2018) Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight 3(17):e121497. doi: 10.1172/jci.insight.121497

Objective: To investigate the suitability of a CD46 antibody as a metastatic castration-resistant prostate cancer (mCRPC) anti-tumor agent.

Summary: CD46 is an excellent candidate for antibody-based therapy development, which has potential to be applicable to both adenocarcinoma and neuroendocrine types of mCRPC that are resistant to current treatment.

Usage: Biotinylated UA20 IgG and Streptavidin-ZAP were mixed at a molar ratio of 1:1. The conjugate was used in cytotoxicity assays and shown to specifically kill the mCRPC cells.

Related Products: Streptavidin-ZAP (Cat. #IT-27)

Browse Articles

Need Support?

Can't find what you're looking for? Contact us, we're here to help!